B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SHMT2

MOLECULAR TARGET

serine hydroxymethyltransferase 2

UniProt: P34897NCBI Gene: 64726 compounds

SHMT2 (serine hydroxymethyltransferase 2) is targeted by 6 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SHMT2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1methotrexate6.00404
2primaquine4.91135
3pyrvinium2.4811
4Duloxetine Hydrochloride0.691
5Oxaprozin0.691
6Papaverine0.691

About SHMT2 as a Drug Target

SHMT2 (serine hydroxymethyltransferase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 6 compounds with documented SHMT2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SHMT2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.